This post was originally published on this site
Extremely premature infants still face daunting risks of sickness or death, even though advances in neonatal-perinatal care have improved infant survival at progressively lower gestational ages. Bronchopulmonary dysplasia — a serious condition of undeveloped lungs — is a leading morbidity in these tiny infants.
Studies have shown that noninvasive respiratory support at birth — rather than immediate intubation and delivery of lung surfactant — improves short-term respiratory outcomes in premature infants born at gestational age 24 weeks-0 days to 27 weeks-6 days.
So, clinicians at the University of Alabama at Birmingham led by Charitharth Vivek Lal, M.D., and Vivek Shukla, M.D., asked whether the same was true for the tiny newborns at the limits of viability, whom they categorize as “nano-preterm” infants — those born at gestational age 22 weeks-0 days to 23 weeks-6 days. These nano-preterms compose a highly specialized niche subgroup that is considerably more immature and has much higher risks of mortality and morbidity than the 24- through 27-week gestational age preterms, Lal says.
A full-term pregnancy is 39 to 40 weeks.
In one of the largest studies of this population, UAB researchers did a retrospective analysis of 230 consecutively born, eligible nano-preterm infants born from January 2014 through June 2021 at the UAB level IV neonatal intensive care unit. Eighty-eight infants in the noninvasive group were those whose first intubation attempt was more than 10 minutes after birth, and 142 infants in the invasive respiratory support at birth were those intubated within 10 minutes after birth. Unlike in several previous studies of slightly older pre-term infants, Lal and colleagues found no benefits for the noninvasive respiratory support of those nano-preterm infants, as measured by the composite outcome of bronchopulmonary dysplasia or death by 36 weeks postmenstrual age.
Some 94.3 percent of the noninvasive group and 90.9 percent of the invasive group had bronchopulmonary dysplasia or death by 36 weeks, which was not a significant difference. The clinicians did see that severe intraventricular hemorrhage or death by 36 weeks was lower in the invasive respiratory support group, a trend that will require a larger number of infants to confirm.
“This cohort study’s findings suggest that noninvasive respiratory support in the first 10 minutes after birth is feasible but may not be associated with a decrease in the risk of bronchopulmonary dysplasia or death compared with intubation and early surfactant delivery in nano-preterm infants,” said Lal, an associate professor in the UAB Department of Pediatrics, Division of Neonatology. Shukla is an assistant professor in the Division of Neonatology.
The average weight of the noninvasive nano-preterm infants was 1 pound 4.4 ounces, and the average weight of the invasive preterm infants was 1 pound 2.4 ounces.
The study, “Hospital and neurodevelopmental outcomes in nano-preterm infants receiving invasive vs noninvasive ventilation at birth,” is published in the journal JAMA Network Open.
Co-authors with Lal and Shukla are Grant Imbrock, Colm P. Travers, Namasivayam Ambalavanan and Waldemar A. Carlo, UAB Department of Pediatrics, Division of Neonatology; and J. Paige Souder, Muhan Hu and A.K.M. Fazlur Rahman, Department of Biostatistics, UAB School of Public Health.
Support came from National Institutes of Health grant HL141652, UAB and Children’s of Alabama.
Pediatrics is a department in the Marnix E. Heersink School of Medicine at UAB.
Story Source:
Materials provided by University of Alabama at Birmingham. Original written by Jeff Hansen. Note: Content may be edited for style and length.